Delivery Order SPE2DB24D1021-SPE2DB25FEZNG
- Not listed
- The Defense Logistics Agency awarded a $9,133.25 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Dupixent 300 mg/2 ml pen injections. This is a firm fixed price delivery order with an ultimate completion date of July 29, 2025, representing a short-duration pharmaceutical supply contract. The award carries no set-aside designation, indicating it was competitively awarded through open procurement processes. AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,979.13 for Dupixent 300 mg/2 mL pen injectors on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price contract, which has no set-aside designation, represents a competitively awarded procurement supporting federal medical supply needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a $6,760.63 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectors, with a completion date of August 1, 2025. This is a firm fixed price, non-set-aside contract with place of performance in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's larger contract vehicle with DLA, reflecting the company's role as a critical pharmaceutical supplier to federal healthcare systems....
- The Defense Logistics Agency awarded a delivery order valued at $12,151.38 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $27,256.30 on August 7, 2025, for the supply of Dupixent 300 mg/2 mL pen injections. The contract represents a firm fixed-price delivery order with an ultimate completion date of August 8, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $35,657.00 to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Dupixent 200 mg/1.14 ml pen injectors. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract specifies a place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $11,468.93 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors, with a completion date of August 12, 2025. This firm fixed-price contract represents a non-competitive set-aside delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The vendor will perform this work from its corporate office in Conshohocken, Pennsylvania, where...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FEZNGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $12,465.70 to supply Dupixent 300 mg/2 mL pen injectors on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price, non-set-aside contract represents a routine pharmaceutical delivery under the company's existing indefinite delivery vehicle with DLA. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen Drug Corp's substantial indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This comprehensive global pharmaceutical support vehicle enables the company to supply a wide range of brand-name and generic pharmaceuticals, specialty medications, and medical supplies to support military healthcare systems worldwide. The Dupixent delivery fulfills the Defense Health Agency and broader military healthcare system's demand for this specialty biologic medication used in treating inflammatory conditions, consistent with AmerisourceBergen's extensive portfolio of federal pharmaceutical procurement services.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.5k | 8/11/25 |